DeYuan Pharmaceutical: The drug registration certificate for Dapagliflozin and Metformin Sustained-Release Tablets has been issued by the National Medical Products Administration.

Deyuan Pharmaceutical Announcement: On April 3, 2026, the company received the drug registration certificate issued by the National Medical Products Administration for the extended-release tablets of Dapagliflozin and Metformin Hydrochloride, which were filed as a Class 4 chemical drug application, and deemed to have passed consistency evaluation. The extended-release tablets of Dapagliflozin and Metformin Hydrochloride are a compound preparation composed of Dapagliflozin and Metformin Hydrochloride, combining two different mechanisms of action of blood glucose-lowering drugs to improve blood glucose control in adult patients with type 2 diabetes.